1.1.1 To compare EFS in patients with newly diagnosed T-ALL and T-LLy who are randomized to a modified ABFM backbone versus bortezomib plus the modified ABFM backbone.
1.2 Secondary Aims
1.2.1 To determine the safety and feasibility of modifying standard therapy for T-ALL and T-LLy based on the results of UKALL 2003, which includes a dexamethasone-based Induction, additional doses of pegaspargase (PEG-ASP) during Induction and Delayed Intensification (DI), and dexamethasone pulses during Maintenance therapy
This is a prospective, observational study of standard medical care for Polycythemia Vera (PV). The purpose of the study is to find out more information about people with PV, follow the course of the disease in these people, and find out how the disease and standard medical care affect the daily life of people being treated for PV. The use of healthcare resources will also be studied.